Clinical Trial Update: Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies [Phase 1]

View source ↗

Summary

Phase I trial update of milatuzumab (anti-CD74/hLL1) antibody therapy in B cell malignancies, including non-Hodgkin lymphoma and chronic lymphocytic leukemia; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Milatuzumab (milatuzumab)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Status: COMPLETED